Alumis: Could This Broken Immunology IPO Become The Next Amgen?
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
bovnews16h
Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
2 Passive Income Stocks to Load Up On in October
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay
IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower ...
Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
BioWorld3d
Prime’s $3.61B Bristol Myers deal is year’s fourth largest
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. (BMS) in a research collaboration and license agreement totaling $3.61 billion. The two companies ...
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb ...
bovnews3d
BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company ...
TMCnet4d
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr.